Commentary: India and ASEAN are growing apart. Blame tariffs
Ties between India and the 10-member Association of Southeast Asian Nations (ASEAN) are already fraying: They're being pushed into different camps, and the free trade agreement they signed in 2010 could become an unexpected victim of the turmoil.
Trump might be the immediate cause of this rift, but, as always, China's massive manufacturing overcapacity is at the heart of the problem. Even if no country knows what rates they or others will face, everyone can be reasonably certain that Beijing's tariffs will be the highest of all.
Unfortunately, this also means that there's a big incentive to help Beijing game the system enough that we all trust each other less.
GAINING FROM CHINA'S OVERCAPACITY
Many Asian countries are reasonably pleased at the thought that duties on their exports will be lower than on those out of China: They've all been searching for a way to regain a sliver of competitiveness, and this might help.
But the same nations are also a little scared. They fear a flood of underpriced Chinese goods, once meant for the US, will inundate their fledgling manufacturing sectors.
In fact, that's already happening to an extent, and policymakers are responding. Vietnam has introduced anti-dumping tariffs on certain kinds of Chinese steel; Indonesia has banned direct-shipping e-commerce apps like Temu.
But, for some, there's also the tempting possibility that China's overcapacity can be turned from an enemy into an ally.
Any country that remains integrated both with China and those that are putting up tariff walls could, if it wanted, become a location for the trans-shipment of goods. Instead of paying the higher China levies, importers would pay lower ones imposed on the third country – and share a bit of the take with local partners.
Tariff arbitrage could become as profitable in the future as interest rate arbitrage is today. The more countries that impose anti-dumping duties on China, the more money the successful trans-shipper would make.
The US, for one, is already very concerned that parts of ASEAN might take this route – which is why Trump's trade deal with Vietnam included a clause that any goods suspected of being trans-shipped would pay double tariffs.
CLOSED-OFF BLOCS A NIGHTMARE FOR INDIA
For countries like India, it's an even greater fear. India's commerce minister caused a bit of a stir recently when he described ASEAN as 'China's B-team'. That was certainly impolitic. But, perhaps, not entirely unjustified.
New Delhi has been trying to update its free trade agreement with ASEAN for a while. Its particular focus has been to tighten rules-of-origin requirements – the way in which you ensure that a free trade agreement only benefits local producers in both countries, not those shipping goods that originate elsewhere.
Indian officials feel that ASEAN has been going slow on these discussions. Meanwhile, news broke in May that the bloc had expanded the scope of its parallel FTA with China. They achieved that in double-quick time – negotiations only started in November 2022 – which raised a few eyebrows in New Delhi.
Some in India, clearly including its commerce minister, now seem to think that tariff-free trade with Southeast Asia is the same as opening your market to China. That isn't true – or, at any rate, not yet. But the fact is that member states simply aren't doing enough to reassure their other trading partners, including India.
It would be a nightmare for most countries, including India, if closed-off blocs were to replace today's open trading system. Yet Trump's actions, when combined with China's overcapacity, are taking us there.
Any country that wants to trade with both sides of the divide – which, clearly, many in Southeast Asia would prefer – will also need to be able to be very transparent about the goods it is exporting, and how much value has been added domestically.
In other words, it's ASEAN's move: They will have to step up and give most of their trading partners, not just India and the US, a clearer view into their supply chains.
The US is clearly worried that some countries will evade its tariffs. Those concerns will be shared, especially by India. New Delhi seems to believe that, if world trade blocs form, then ASEAN has already chosen its side – and it won't be the one India picks. Trade's impossible without trust, and these two partners will have to work to rebuild it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
International Business Times
an hour ago
- International Business Times
Appeals Court Questions Trump's Use of Emergency Powers to Justify Tariffs
A US federal appeals court raised serious doubts about President Donald Trump's authority to impose broad tariffs under emergency powers. During a hearing in Washington, D.C., judges questioned whether the International Emergency Economic Powers Act (IEEPA) grants the president the legal right to impose tariffs on allied nations like Canada, China, and Mexico. Trump had used IEEPA to introduce what he called "reciprocal" tariffs in April and further increased them in February. The case now before the U.S. Court of Appeals for the Federal Circuit was brought by five small businesses and 12 Democratic-led states. They argue that Trump overstepped his powers and that only Congress has the constitutional right to set tariffs and taxes. Government lawyer Brett Shumate defended Trump's move, saying IEEPA gives the president broad authority in economic emergencies, including regulating imports. But Judge Jimmie Reyna responded, "IEEPA doesn't even mention tariffs." Several judges appeared skeptical throughout the 90-minute hearing, which concluded without a ruling date. The outcome of this case could have major implications. Trump, who made tariffs a key trade tool during his second term, claims they helped address unfair trade practices and boosted U.S. manufacturing. He cited the U.S. trade deficit and illegal fentanyl imports as justification. However, critics argue these reasons do not constitute an "extraordinary threat" under the law. Earlier this year, a lower court also ruled that IEEPA does not support tariffs based on long-term trade imbalances. The appeals court has allowed the tariffs to stay in place while legal challenges continue. With customs duties now generating over $100 billion in revenue this fiscal year, tariffs have become a significant funding source. Still, economists warn that they raise consumer prices and disrupt supply chains. The Trump administration argues that removing tariff power could harm trade negotiations, although recent deals with the EU, Japan, and others have moved forward. Trump has warned of further tariff hikes on countries not reaching new trade deals by August 1. The final decision in this case is likely to head to the U.S. Supreme Court if either side loses.
International Business Times
an hour ago
- International Business Times
Asian Markets Tumble After Trump's Tariffs Announcement; Investors Watch US. Jobs Report Closely
Investors felt the jitters as Asian markets dropped on Friday after U.S. President Donald Trump signed an executive order imposing tariffs ranging between 10% and 41% on imports from countries such as India, Taiwan, Thailand, South Korea, and Turkey. South Korea's KOSPI dropped 3%, Taiwan's TWII slipped 0.9% to its lowest in two months, Japan's Nikkei was off 0.4%, and MSCI's broadest index of Asia-Pacific shares outside Japan lost 0.7%, also marking a 1.8% decline for the week. Chinese blue chips were little changed, and Hong Kong's Hang Seng inched higher by 0.2%. Freepik The tremors were also felt in European markets, where futures for EUROSTOXX 50 fell 0.2%. Futures for the Nasdaq and the S&P 500 fell 0.2% in reaction to Amazon's earnings, which fell short of expectations and caused its shares to drop 6.6% in extended trading. Apple provided a little boost to sentiment, up 2.4% on strong revenue guidance. Tariffs Create Uncertainty Ahead of Fed Decision The new tariffs range from 25% on Indian goods and 20% on Taiwanese exports to 19% on Thai imports. The new tariff rate for South Korea is 15% down from the earlier announced 25%. Canadian goods not covered under the USMCA are subject to a new 35% tariff rate, up from 25%. Mexico was relieved as it got a 90-day break to negotiate further. Markets reacted with caution. Wall Street gave up early gains on Thursday. The Dow dropped 0.75%, the S&P 500 ended down more than 0.3%, and the Nasdaq closed slightly in the red. Fresh U.S. inflation data suggested that prices were rising, in part because of tariffs. Fed fund futures now show just a 39% probability of a rate cut in September, down from 65% before the Fed stuck to its announced rates on Wednesday. Dollar Gains, Bond Yields Steady Amid Caution The dollar advanced as traders trimmed rate-cut wagers. The dollar's index rose to 100.1, its highest in two months, with a 2.5% weekly gain, the most since 2022. The yen weakened 0.8% to 150.7 per dollar after the Bank of Japan kept rates on hold and sounded a cautious note. The Canadian dollar was steady even as tariffs increased. The yield on the 10-year United States Treasury note edged up to 4.374%. Commodities Mixed as Oil Holds Steady, Gold Loses Ground Oil prices remained flat after a 1% decline on Wednesday. U.S. crude rose 0.1% to $69.36 a barrel, and Brent gained 0.2% to $71.84. On the spot market, gold was down slightly, to $3,286 an ounce, as investors balanced a flood of safe-haven demand against rising yields and a stronger dollar.
International Business Times
an hour ago
- International Business Times
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.
